Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on developing therapies for neurodegenerative and metabolic disorders, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage. Durkacz noted that this area remains unmet by currently available treatments, underscoring the potential impact of Lucid-MS for patients suffering from MS.
In addition to Lucid-MS, Durkacz highlighted Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. The product is marketed by Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), a company in which Quantum retains a 19.84% ownership stake as of March 31, 2026, and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of rights to develop similar products for pharmaceutical and medical uses.
Looking ahead, Durkacz announced the company’s upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. This trial represents a critical milestone for Quantum BioPharma, as positive results could position Lucid-MS as a novel treatment for MS-related mobility loss. The company’s wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, and no approved therapy currently reverses this process, making Lucid-MS a potentially transformative therapy.
The podcast appearance comes as Quantum BioPharma continues to build its portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company’s dual focus on both a clinical-stage drug candidate and a commercial consumer product provides a diversified revenue stream and potential near-term cash flow from unbuzzd(TM) sales, while Lucid-MS targets a large unmet medical need in the MS market. According to the National Multiple Sclerosis Society, nearly 1 million people in the United States live with MS, and many experience progressive mobility loss that current treatments do not adequately address.
For investors, the progression of Lucid-MS into Phase 2 trials and the commercial performance of unbuzzd(TM) are key catalysts to watch. The full press release and additional information about Quantum BioPharma are available in the company’s newsroom at https://ibn.fm/QNTM. The BioMedWire podcast episode can be accessed through the BioMedWire platform at https://www.BioMedWire.com, which specializes in communications for the biotechnology, biomedical, and life sciences sectors.
The implications of Quantum BioPharma’s developments extend to patients, the pharmaceutical industry, and investors. If Lucid-MS successfully demonstrates efficacy in restoring mobility in MS patients, it could address a critical gap in MS treatment, potentially improving quality of life for millions. For the industry, a reversal of myelin degradation would represent a paradigm shift in MS therapy. For investors, the combination of a high-risk/high-reward drug candidate and a revenue-generating consumer product offers a balanced risk profile. The upcoming Phase 2 trial results will be closely watched by the medical and investment communities alike.
